Skip to main content

Table 1 Analyses of HMA combinations with AraC on BCP-ALL cells

From: Decitabine demonstrates antileukemic activity in B cell precursor acute lymphoblastic leukemia with MLL rearrangements

  Drug combination effect
AZA + AraC AZA + AraC (24 h) AraC + AZA (24 h) DEC + AraC DEC + AraC (24 h) AraC + DEC (24 h)
SEM Metabolism 0.095 0.045 0.004 0.022 − 0.039 − 0.077
Proliferation 0.064 0.006 0.001 0.017 − 0.048 0.041
RS4;11 Metabolism 0.076 − 0.055 − 0.018 0.128 − 0.032 − 0.043
Proliferation 0.016 0.044 − 0.003 0.000 0.025 0.076
  1. Drug combination effect: difference between the observed and the expected inhibition (E) of combined treatment. E is calculated as follows: E = (A + B) − (A*B); A is inhibition effect of drug A; B inhibition effect of drug B values > 0: synergistic, values < 0: antagonistic